Leap Investments’s bluebird bio BLUE Stock Holding History

Leap Investments’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-394	Closed	-$234K	–	409
2020 Q1	$234K	Buy	+394	New	+$384K	0.34%	124

Other funds holding BLUE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Leap Investments's BLUE Position: Q2 2020 in Review

Leap Investments sold out of bluebird bio (BLUE) in Q2 2020, closing a stake of 394 shares — an estimated $234K sold.

Leap Investments first reported a position in BLUE in Q1 2020 and held it in 1 quarter. The position peaked at $234K in Q1 2020. 278 funds tracked by Wall St. Rank hold BLUE as of Q2 2020.

Leap Investments reported no remaining bluebird bio position as of Q2 2020 after selling out during the quarter.
Leap Investments sold 394 bluebird bio shares in Q2 2020, an estimated $234K.
Leap Investments first reported a position in bluebird bio in Q1 2020 and held it in 1 quarter.
Leap Investments's bluebird bio position peaked at $234K in Q1 2020.
278 funds tracked by Wall St. Rank held bluebird bio as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.